title: Laser prostatectomy in patients on anticoagulant therapy or with bleeding disorders.
abstract: OBJECTIVE
  Bleeding disorders or the use of anticoagulant medication are contraindications to transurethral prostate resection in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Laser prostatectomy has proved to be adequate surgical therapy with less blood loss than transurethral prostate resection.
  
  
  METHODS
  A prospective, controlled study was done in patients at high risk (HR) with LUTS suggestive of BPH. They were treated with contact laser prostatectomy (CLP) or the combination of CLP with visual laser ablation prostatectomy (VLAP). HR was defined as bleeding disorders or anticoagulants use. As a control, men at normal risk with LUTS suggestive of BPH were treated with CLP. Patients completed validated questionnaires and underwent urodynamics at baseline and 6 months postoperatively.
  
  
  RESULTS
  A total of 75 patients were included, namely 19 in the HR-CLP group, 11 in the HR-CLP-VLAP group and 45 in the normal risk CLP group. Obstruction relief, and symptomatic and subjective improvement were equal in all 3 groups. Effective capacity (maximum cystometric capacity minus post-void residual volume) also improved significantly in all except the HR-CLP group. Maximum urine flow improved in all groups but not significantly in the HR-CLP group. Intraoperative and postoperative complications were slightly higher in HR cases. However, blood transfusion was never necessary and there was no mortality.
  
  
  CONCLUSIONS
  CLP and especially CLP-VLAP perform almost as well in HR cases compared with CLP in those at normal risk. These procedures are safe for men at HR with LUTS suggestive of BPH.
authors.affiliation: Department of Urology (HP G 05.201), University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. HvMelick@hotmail.com
authors.forename: Harm H E
authors.initials: HH
authors.lastname: van Melick
authors.forename: Ger E P M
authors.initials: GE
authors.lastname: van Venrooij
authors.forename: Tom A
authors.initials: TA
authors.lastname: Boon
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000503:physiopathology; D000075202:Contraindications; D006452:Hemoglobinometry; D006474:Hemorrhagic Disorders / Q000150:complications*; D006801:Humans; D017075:Laser Coagulation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis / Q000503:physiopathology; D011446:Prospective Studies; D011468:Prostatectomy / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000601:surgery*; D012307:Risk Factors; D020728:Transurethral Resection of Prostate; D001748:Urinary Bladder Neck Obstruction / Q000097:blood / Q000601:surgery*; D014563:Urodynamics / Q000502:physiology
chemical_list: D000925:Anticoagulants